Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.5652W HIGH $21.18
Volume
3.24 M
Value Traded
24.28 M
Short % Float
7.86%
-3.2%Week
+13.91%1 Month
+15.52%3 Month
+56.7%6 Month
+116.38%5 Year
+36.11%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.28 B
EPS (TTM)
0.45
P/E Ratio
43.49
Ent. Value
8.72 B
Total Shares
319.35 M
Float Shares
143.63 M
Insiders
55.02%
Institutions
48.22%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AMRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Amneal Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Amneal Pharmaceuticals, Inc.
166Total events
2Upcoming
54Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲FDA Approvaliohexol injectionApprovedFDA Decision
FDA approval of additional strengths and vial presentations of iohexol injection
radiographic contrast agent for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity imaging proceduressource ↗
▲Product Launchiohexol injectionApprovedPost-Market
Planned launch of newly approved iohexol injection presentations
radiographic contrast agentsource ↗
◆Oral PresentationPresentation
Amneal presentation at Goldman Sachs 47th Annual Global Healthcare Conference 2026
▲Interim AnalysisCREXONTApprovedTrial
Full study population interim Phase 4 ELEVATE-PD results announced
Parkinson's diseasesource ↗
●Oral PresentationCREXONTApprovedPresentation
Presentation at ATRMD 2026 Congress
Parkinson's diseasesource ↗
▲FDA ApprovalFDA Decision
FDA approval of romidepsin injection solution
cutaneous T-cell lymphomasource ↗
▲Label ExpansionCREXONTApprovedFDA Decision
FDA approved labeling update for sprinkling administration
Parkinson's diseasesource ↗
▲Oral PresentationCREXONTApprovedPresentation
Positive interim Phase 4 ELEVATE-PD results presented at AAN 2026
Parkinson's diseasesource ↗
▲Product Launchalbuterol sulfate inhalation aerosolApprovedPost-Market
U.S. launch of albuterol sulfate inhalation aerosol
bronchospasm, exercise-induced bronchospasmsource ↗
▲Product LaunchPost-Market
U.S. launch of beclomethasone dipropionate HFA inhalation aerosol
asthma maintenance treatmentsource ↗
▲Product LaunchPost-Market
Launch of bimatoprost ophthalmic solution 0.01%
reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertensionsource ↗
◆Oral PresentationPresentation
Fireside chat at Barclays 28th Annual Global Healthcare Conference
▲Enrollment CompleteCREXONTApprovedTrial
Enrollment completed in ELEVATE-PD
Parkinson's diseasesource ↗
▲Product Launchiohexol injectionApprovedPost-Market
Expected launch of iohexol injection
radiographic contrast agentsource ↗
▲FDA ApprovalBoncresaApprovedFDA Decision
FDA approval of Boncresa (denosumab-mobz) as biosimilar to Prolia
osteoporosis-related conditionssource ↗
▲FDA ApprovalOziltusApprovedFDA Decision
FDA approval of Oziltus (denosumab-mobz) as biosimilar to XGEVA
oncology-related conditionssource ↗
▲FDA ApprovalFDA Decision
FDA approval of epinephrine injection in single- and multi-dose vials
emergency treatment of allergic reactions (Type 1) including anaphylaxis; increase mean arterial blood pressure in adult patients with hypotension associated with septic shocksource ↗
▲Interim AnalysisCREXONTApprovedTrial
Positive interim Phase 4 ELEVATE-PD results for CREXONT
Parkinson's diseasesource ↗
●Oral PresentationCREXONTApprovedPresentation
Poster #92 presented at PSG Annual Meeting
Parkinson's diseasesource ↗
▲FDA Approvalalbuterol sulfate inhalation aerosolApprovedFDA Decision
FDA approval of albuterol sulfate inhalation aerosol
treatment or prevention of bronchospasm in adults and children 12 years of age and older with reversible obstructive airway diseasesource ↗
▲FDA ApprovalFDA Decision
FDA approval of cyclosporine ophthalmic emulsion 0.05%
dry eye syndromesource ↗
▲FDA Approvaliohexol injectionApprovedFDA Decision
FDA approval of first generic iohexol injection
radiographic contrast agent for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity imagingsource ↗
●Milestone PaymentCorporate
$22.5 million milestone paid for BLA submission of biosimilar candidate to XOLAIR
▲Tentative ApprovalFDA Decision
FDA tentative approval for beclomethasone dipropionate HFA inhalation aerosol
asthmasource ↗
▲Product LaunchBREKIYAApprovedPost-Market
U.S. commercial launch of Brekiya autoinjector
acute treatment of migraine with or without aura and acute cluster headachessource ↗
▲FDA Approvalbeclomethasone dipropionate inhalation aerosolApprovedFDA Decision
FDA approval of beclomethasone dipropionate inhalation aerosol (generic QVAR)
▲Product Launchrisperidone extended-release injectable suspensionApprovedPost-Market
Product launch planned for Q4 2025
schizophrenia; maintenance treatment of Bipolar I disordersource ↗
●Timing GuidanceADL-018Presentation
BLA submission expected for ADL-018
Chronic Idiopathic Urticaria (CIU) or Chronic Spontaneous Urticaria (CSU)source ↗
●BLA SubmissionRegulatory Filing
BLA submission for biosimilar to XOLAIR (omalizumab)
moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, food allergies, chronic spontaneous urticariasource ↗
▲FDA ApprovalFDA Decision
FDA approval of bimatoprost ophthalmic solution 0.01%
open-angle glaucoma or ocular hypertensionsource ↗
▲FDA ApprovalFDA Decision
FDA approval of sodium oxybate oral solution ANDA
cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsysource ↗
▲FDA Approvalrisperidone extended-release injectable suspensionApprovedFDA Decision
FDA approval of risperidone extended-release injectable suspension
schizophrenia; maintenance treatment of Bipolar I disordersource ↗
▲FDA ApprovalBREKIYAApprovedFDA Decision
FDA approval of Brekiya autoinjector
acute treatment of migraine and cluster headache in adultssource ↗
Past FDA Catalysts and PDUFA Decisions
How AMRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-09 | Sodium Bicarbonate | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$52M
Pipeline Value
$13.3B
Commercial Value
Undervalued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 82%
Small Cap(rank 540 of 658)
Percentile Rank
Amneal Pharmaceuticals, Inc. faces pipeline headwinds (25/100), with $83M risk-adjusted pipeline value, led by KSHN001126 in Healthy Postmenopausal Women (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $3.1B x 4.3 = $13.3B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Oral solid | $715M | $701M | +2% |
| Central nervous system | $361M | $301M | +20% |
| Government label | $285M | $184M | +54.4% |
| Other Dosage Forms | $256M | $234M | +9.3% |
| Transdermal | $245M | $174M | +40.3% |
| Ephinephrine Auto-Injector | $222M | $223M | -0.5% |
| Hormonal Allergy | $163M | $139M | +17.6% |
| Oral liquid | $54M | $89M | -39.4% |
| Other Therapeutic Classes | $50M | $30M | +65.7% |
| Institutional | $36M | $41M | -12.4% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KSHN001126 Small moleculeCompletedNCT06467201 | Healthy Postmenopausal Women | Phase 1 | COMPLETED | 18 | Mar 12, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every AMRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CREXONT | Parkinson's disease | Phase 4 | 2026-06-05 | Good On time increase: from IR CD LD 3.33 hours, from IR CD LD COMT 3.20 hours, from RYTARY 3.03 hours; Off time reduction: from IR CD LD 3.20 hours, from IR CD LD COMT 2.96 hours, from RYTARY 2.4 hours; MDS UPDRS improvement: from IR CD LD -14.6 points, from IR CD LD COMT -9.9 points, from RYTARY -10.0 pointsRead More | Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT in Parkinson's DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BUCHI J KEVINDirector | Option | 20,445 95,522 held | $14.45 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AMRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 1 % (150 %) | 9.37 M | 541.19 K | 79.95% ( 240.44 K) |
AMRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AMRX ranks across every disease it competes in
Competitive Position is a premium feature
See how AMRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAMRX News
AMRXAmneal to Report Third Quarter 2026 Results on November 3, 2026
Amneal Pharmaceuticals, Inc. will announce its third quarter 2026 financial results on November 3, 2026, before the market opens. The company will also host an audio webcast at 8:30 a.m. ET for investors. Amneal is recognized for its commitment to providing affordable and innovative medicines across various segments.
Read more →AMRX▲ +7.7%on this news
Amneal Announces FDA Approval and Launch of Lanreotide Injection
Amneal Pharmaceuticals has received FDA approval for its lanreotide injection, which is now available for immediate launch. This product is a significant addition to their complex injectables portfolio and is expected to drive growth in their Affordable Medicines business. Lanreotide is indicated for treating acromegaly and neuroendocrine tumors, with substantial market potential.
Read more →AMRXAmneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
Amneal Pharmaceuticals has completed its acquisition of Kashiv BioSciences, establishing a fully integrated global platform for biosimilars. This strategic move is designed to enhance Amneal's growth prospects and capitalize on the upcoming loss of exclusivity for various biologics. The integration aims to combine both companies' capabilities, allowing for multiple biosimilar launches annually.
Read more →AMRXAmneal Reports Second Quarter 2026 Financial Results
Amneal Pharmaceuticals reported strong financial results for Q2 2026, with net revenue of $796 million and a net income of $58 million, marking a 157% increase from the previous year. The company raised its full-year guidance for 2026, citing robust performance across its diversified portfolio. Additionally, a successful debt repricing is expected to lower future interest costs, further enhancing financial stability.
Read more →AMRXAmneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
Amneal Pharmaceuticals has received FDA approval for additional strengths and vial presentations of iohexol injection, enhancing its injectable contrast portfolio. The new products include 350 mg iodine/mL in various vial sizes and 300 mg iodine/mL in a 50 mL vial. This expansion aims to meet the majority of U.S. market demand and showcases Amneal's commitment to high-quality healthcare solutions.
Read more →AMRXAmneal to Report Second Quarter 2026 Results on July 30, 2026
Amneal Pharmaceuticals, Inc. has announced it will report its second quarter 2026 financial results on July 30, 2026, before the market opens. The company will host an audio webcast at 8:30 a.m. ET for investors. Interested parties can register for the webcast through the company's Investor Relations website.
Read more →AMRXAmneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector
Amneal Pharmaceuticals and Adalvo have announced that the FDA has accepted two Abbreviated New Drug Applications (ANDAs) for generic tirzepatide injection. These applications aim for approval of prefilled pen presentations for treating type 2 diabetes and chronic weight management. This milestone highlights the companies' commitment to advancing complex injectable medicines and improving patient access to affordable therapies.
Read more →AMRXAmneal’s New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program
Amneal Pharmaceuticals has been chosen for the FDA PreCheck Pilot Program for its new sterile manufacturing facility in Brookhaven, NY. This facility aims to enhance the production of sterile injectable medicines and address market supply needs. It reflects Amneal's commitment to domestic manufacturing and aims to strengthen the U.S. pharmaceutical supply chain. The project will also create skilled jobs and improve manufacturing efficiency.
Read more →AMRXZambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Zambon and Amneal Pharmaceuticals received a positive opinion from the CHMP for Hopledo® (IPX203), a modified-release formulation of levodopa/carbidopa for adults with Parkinson's disease experiencing moderate to severe motor fluctuations. The recommendation is based on the Phase 3 RISE-PD trial, which showed significant improvements in 'Good ON' time with fewer doses compared to standard treatments. If approved by the European Commission, Hopledo® will be available starting October 2026.
Read more →AMRXAmneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT in Parkinson's Disease
Amneal Pharmaceuticals announced positive interim results from the Phase 4 ELEVATE-PD study, showing significant benefits of CREXONT in Parkinson's disease treatment. The full study population of 214 patients reported increases in 'Good On' time and improvements in motor function after switching to CREXONT from other therapies, including RYTARY. The findings support CREXONT's efficacy and safety and will contribute to ongoing evaluations over a 12-month follow-up period.
Read more →AMRX▲ +5%on this newsshared move
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Amneal Pharmaceuticals announced that the U.S. FDA has approved its romidepsin injection solution, offering a ready-to-use formulation that eliminates the need for reconstitution. This approval grants Amneal a Competitive Generic Therapy designation, providing 180 days of market exclusivity and bolstering its injectables portfolio. The product is indicated for treating cutaneous T-cell lymphoma in adult patients who have had prior systemic therapy. While the approval highlights a significant advancement in Amneal’s product offerings, it also presents potential adverse reactions that could affect patient acceptance in the market.
Read more →AMRXAmneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
Amneal Pharmaceuticals will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026. Chirag Patel, Co-CEO, will present on June 9 at 8:40 AM EDT. This event offers Amneal an opportunity to highlight its diverse portfolio of medicines and engage with investors.
Read more →AMRXAmneal Reports First Quarter 2026 Financial Results
Amneal Pharmaceuticals reported strong financial results for the first quarter of 2026, with net revenue of $723 million, marking a 4% increase year-over-year. The company saw a notable rise in net income, up by 411%, and confirmed its increased guidance for the full year 2026. The performance was particularly driven by their Specialty business, which benefited from product launches, including CREXONT® and BREKIYA® autoinjector. Overall, Amneal's diversified portfolio appears to be generating robust growth, suggesting a positive outlook for the company.
Read more →AMRXAmneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
Amneal Pharmaceuticals has announced its agreement to acquire Kashiv BioSciences in a move aimed at establishing a global biosimilars leader. The deal involves $375 million in cash and equity at closing, with additional potential payments linked to regulatory milestones. Following the announcement, Amneal reported strong preliminary financial results for Q1 2026 and raised its full year guidance, indicating robust performance across its business segments. The transaction is positioned to leverage significant growth in the biosimilars sector ahead of a projected $300 billion loss-of-exclusivity wave in global biologics over the next decade.
Read more →AMRXAMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Amneal Pharmaceuticals reported a strong performance for Q1 2026, with net revenues reaching $723 million, reflecting a 4% increase from the previous year. The company's GAAP net income soared to $62 million, a notable increase of 411% year-over-year. Amneal also reaffirmed its previously announced increased guidance for the full year 2026, highlighting confidence in its growth prospects. However, the firm faced a decline in AvKARE revenues and potential risks from ongoing acquisitions. Overall, the results indicate a robust start to the year fueled by strong business drivers and product launches.
Read more →AMRXKashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
Kashiv BioSciences has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals. This merger aims to create a fully integrated global biosimilar leader, combining Kashiv's expertise in biosimilars with Amneal's commercialization capabilities. The transaction is expected to close in the second half of 2026, pending shareholder and regulatory approvals.
Read more →AMRXAmneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
Amneal Pharmaceuticals announced positive interim results from its Phase 4 ELEVATE-PD study, showing that patients switching to CREXONT experienced significant increases in daily 'Good On' time and reductions in 'Off' time. The study involved 111 patients and highlighted the efficacy of CREXONT across various prior treatments, including RYTARY. The findings suggest that CREXONT could enhance symptom management for Parkinson's disease patients.
Read more →AMRXAmneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
Amneal Pharmaceuticals has launched its first two metered-dose inhalation products in the U.S., namely albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol. Both products, approved by the FDA in 2025, aim to enhance patient access to respiratory treatments. The launch signifies Amneal's entry into the complex inhalation category, with further products in development.
Read more →AMRXAmneal Launches Bimatoprost Ophthalmic Solution, 0.01%
Amneal Pharmaceuticals has launched bimatoprost ophthalmic solution 0.01%, a generic equivalent of LUMIGAN, aimed at reducing intraocular pressure in glaucoma patients. This addition to their Affordable Medicines portfolio is expected to enhance access to essential treatments as glaucoma cases rise. The product's launch is anticipated to drive growth within Amneal's segment.
Read more →AMRXAmneal to Report First Quarter 2026 Results on May 1, 2026
Amneal Pharmaceuticals, Inc. will announce its first quarter 2026 financial results on May 1, 2026, before the market opens. An audio webcast is scheduled for 8:30 a.m. ET, providing investors with access to the results and a conference call. The company emphasizes its commitment to affordable and innovative medicines.
Read more →About Amneal Pharmaceuticals, Inc.
HeadquartersBridgewater
Founded2002
BIOPHARMAWATCH ELITE PLUS
Trade the next AMRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime